Showing results (451-460 of 656) with videos related to
Sort By:
Pageof 66
Thrombosis and Haemostasis|October 9, 2008
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery diseaseOscar O Braun, Matilda Johnell, Christoph Varenhorst, et al.Platelets|June 24, 2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjectsChristopher D Payne, Ying G Li, John T Brandt, et al.Thrombosis and Haemostasis|February 19, 2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.Archives of Pathology & Laboratory Medicine|September 18, 1998
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapyR B Fairweather, J Ansell, A M van den Besselaar, et al.Journal of Clinical Pharmacology|February 28, 2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.Archives of Pathology & Laboratory Medicine|November 2, 2006
Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testingAgata Smogorzewska, John T Brandt, Wayne L Chandler, et al.Thrombosis and Haemostasis|January 25, 2008
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.Journal of the American College of Cardiology|December 6, 2008
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivoDavid Erlinge, Christoph Varenhorst, Oscar O Braun, et al.Blood|July 19, 2003
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemiaBryce A Kerlin, S Betty Yan, Berend H Isermann, et al.Investigational New Drugs|February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Harry P Erba, Hamid Sayar, Mark Juckett, et al.Pageof 66